.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Farmers Insurance
Harvard Business School
Fish and Richardson
Julphar
Mallinckrodt
Merck
Deloitte
Chubb

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204275

« Back to Dashboard

NDA 204275 describes BREO ELLIPTA, which is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the BREO ELLIPTA profile page.

The generic ingredient in BREO ELLIPTA is fluticasone furoate; vilanterol trifenatate. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; vilanterol trifenatate profile page.

Summary for 204275

Tradename:1
Applicant:1
Ingredient:1
Patents:14
Formulation / Manufacturing:see details

Pharmacology for NDA: 204275

Suppliers and Packaging for NDA: 204275

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275 NDA GlaxoSmithKline LLC 0173-0859 0173-0859-61 1 TRAY in 1 CARTON (0173-0859-61) > 1 INHALER in 1 TRAY > 14 POWDER in 1 INHALER
BREO ELLIPTA fluticasone furoate; vilanterol trifenatate POWDER;INHALATION 204275 NDA GlaxoSmithKline LLC 0173-0859 0173-0859-14 1 TRAY in 1 CARTON (0173-0859-14) > 1 INHALER in 1 TRAY > 14 POWDER in 1 INHALER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrength0.1MG/INH;EQ 0.025MG BASE/INH
Approval Date:May 10, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:May 15, 2020
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Apr 30, 2018
Regulatory Exclusivity Use:DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
Regulatory Exclusivity Expiration:May 10, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY

Expired Orange Book Patents for NDA: 204275

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013► Subscribe► Subscribe
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
US Army
Federal Trade Commission
Medtronic
Chinese Patent Office
Argus Health
McKinsey
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot